Malignant Fibrous Histiocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major malignant fibrous histiocytoma markets are expected to exhibit a CAGR of 8.67% during 2024-2034.
The malignant fibrous histiocytoma market has been comprehensively analyzed in IMARC's new report titled "Malignant Fibrous Histiocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Malignant fibrous histiocytoma (MFH), also referred to as undifferentiated pleomorphic sarcoma, is a rare and aggressive soft tissue sarcoma. It predominantly affects adults and originates from the connective tissues, often in the extremities, abdomen, or retroperitoneum. This tumor arises from fibroblast and histiocytic cells, which are involved in immune response and tissue repair. The symptoms of the illness can vary based on the tumor's location and size, but common signs include pain, swelling, and a noticeable mass or lump. As the cancer progresses, it might impinge on surrounding structures, causing discomfort and functional impairment. Systemic signs, such as fatigue, fever, and weight loss, can also occur in more advanced cases. The diagnosis of MFH involves a combination of methods, including imaging studies like MRI or CT scans, to visualize the tumor's location and size. A tissue biopsy is also recommended for accurate diagnosis, allowing pathologists to examine the tumor's cellular characteristics under a microscope.
The increasing prevalence of genetic alterations causing gene mutations, deletions, or rearrangements, which can disrupt normal cellular processes, is primarily driving the malignant fibrous histiocytoma market. In addition to this, the inflating utilization of advanced therapeutic interventions, including surgical resection, radiation therapy, and chemotherapy regimens like anthracyclines and ifosfamide, to effectively manage the condition and deter its progression is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive care measures and pain management strategies, as they contribute to enhancing patients' overall quality of life, is further propelling the market growth. Apart from this, the rising usage of targeted therapies aimed at specific genetic mutations or molecular abnormalities associated with MFH is acting as another significant growth-inducing factor. These targeted approaches, such as tyrosine kinase inhibitors and immunotherapies, hold promise for mitigating the disease's aggressive nature and improving patient outcomes. Additionally, the growing awareness and integration of complementary therapies and holistic approaches, including acupuncture, mindfulness techniques, nutritional support, etc., that can prevent metastasis in individuals suffering from the disorder are also augmenting the market growth. Furthermore, the escalating application of novel avenues, such as gene therapies, which aim to modulate or correct the genetic anomalies underlying the condition, is expected to drive the malignant fibrous histiocytoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the malignant fibrous histiocytoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for malignant fibrous histiocytoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the malignant fibrous histiocytoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the malignant fibrous histiocytoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the malignant fibrous histiocytoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current malignant fibrous histiocytoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the malignant fibrous histiocytoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the malignant fibrous histiocytoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the malignant fibrous histiocytoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of malignant fibrous histiocytoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant fibrous histiocytoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant fibrous histiocytoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with malignant fibrous histiocytoma across the seven major markets?
What is the size of the malignant fibrous histiocytoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of malignant fibrous histiocytoma?
What will be the growth rate of patients across the seven major markets?
Malignant Fibrous Histiocytoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for malignant fibrous histiocytoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the malignant fibrous histiocytoma market?
What are the key regulatory events related to the malignant fibrous histiocytoma market?
What is the structure of clinical trial landscape by status related to the malignant fibrous histiocytoma market?
What is the structure of clinical trial landscape by phase related to the malignant fibrous histiocytoma market?
What is the structure of clinical trial landscape by route of administration related to the malignant fibrous histiocytoma market?
The malignant fibrous histiocytoma market has been comprehensively analyzed in IMARC's new report titled "Malignant Fibrous Histiocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Malignant fibrous histiocytoma (MFH), also referred to as undifferentiated pleomorphic sarcoma, is a rare and aggressive soft tissue sarcoma. It predominantly affects adults and originates from the connective tissues, often in the extremities, abdomen, or retroperitoneum. This tumor arises from fibroblast and histiocytic cells, which are involved in immune response and tissue repair. The symptoms of the illness can vary based on the tumor's location and size, but common signs include pain, swelling, and a noticeable mass or lump. As the cancer progresses, it might impinge on surrounding structures, causing discomfort and functional impairment. Systemic signs, such as fatigue, fever, and weight loss, can also occur in more advanced cases. The diagnosis of MFH involves a combination of methods, including imaging studies like MRI or CT scans, to visualize the tumor's location and size. A tissue biopsy is also recommended for accurate diagnosis, allowing pathologists to examine the tumor's cellular characteristics under a microscope.
The increasing prevalence of genetic alterations causing gene mutations, deletions, or rearrangements, which can disrupt normal cellular processes, is primarily driving the malignant fibrous histiocytoma market. In addition to this, the inflating utilization of advanced therapeutic interventions, including surgical resection, radiation therapy, and chemotherapy regimens like anthracyclines and ifosfamide, to effectively manage the condition and deter its progression is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive care measures and pain management strategies, as they contribute to enhancing patients' overall quality of life, is further propelling the market growth. Apart from this, the rising usage of targeted therapies aimed at specific genetic mutations or molecular abnormalities associated with MFH is acting as another significant growth-inducing factor. These targeted approaches, such as tyrosine kinase inhibitors and immunotherapies, hold promise for mitigating the disease's aggressive nature and improving patient outcomes. Additionally, the growing awareness and integration of complementary therapies and holistic approaches, including acupuncture, mindfulness techniques, nutritional support, etc., that can prevent metastasis in individuals suffering from the disorder are also augmenting the market growth. Furthermore, the escalating application of novel avenues, such as gene therapies, which aim to modulate or correct the genetic anomalies underlying the condition, is expected to drive the malignant fibrous histiocytoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the malignant fibrous histiocytoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for malignant fibrous histiocytoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the malignant fibrous histiocytoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the malignant fibrous histiocytoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the malignant fibrous histiocytoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current malignant fibrous histiocytoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the malignant fibrous histiocytoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the malignant fibrous histiocytoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the malignant fibrous histiocytoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of malignant fibrous histiocytoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant fibrous histiocytoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant fibrous histiocytoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with malignant fibrous histiocytoma across the seven major markets?
What is the size of the malignant fibrous histiocytoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of malignant fibrous histiocytoma?
What will be the growth rate of patients across the seven major markets?
Malignant Fibrous Histiocytoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for malignant fibrous histiocytoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the malignant fibrous histiocytoma market?
What are the key regulatory events related to the malignant fibrous histiocytoma market?
What is the structure of clinical trial landscape by status related to the malignant fibrous histiocytoma market?
What is the structure of clinical trial landscape by phase related to the malignant fibrous histiocytoma market?
What is the structure of clinical trial landscape by route of administration related to the malignant fibrous histiocytoma market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MALIGNANT FIBROUS HISTIOCYTOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MALIGNANT FIBROUS HISTIOCYTOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MALIGNANT FIBROUS HISTIOCYTOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MALIGNANT FIBROUS HISTIOCYTOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MALIGNANT FIBROUS HISTIOCYTOMA - UNMET NEEDS
10 MALIGNANT FIBROUS HISTIOCYTOMA - KEY ENDPOINTS OF TREATMENT
11 MALIGNANT FIBROUS HISTIOCYTOMA - MARKETED PRODUCTS
11.1 List of Malignant Fibrous Histiocytoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MALIGNANT FIBROUS HISTIOCYTOMA - PIPELINE DRUGS
12.1 List of Malignant Fibrous Histiocytoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Envafolimab - Alphamab Oncology/Ascletis/3D Medicine
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. MALIGNANT FIBROUS HISTIOCYTOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MALIGNANT FIBROUS HISTIOCYTOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MALIGNANT FIBROUS HISTIOCYTOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Malignant Fibrous Histiocytoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Malignant Fibrous Histiocytoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Malignant Fibrous Histiocytoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Malignant Fibrous Histiocytoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Malignant Fibrous Histiocytoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Malignant Fibrous Histiocytoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Malignant Fibrous Histiocytoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Malignant Fibrous Histiocytoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
16 MALIGNANT FIBROUS HISTIOCYTOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MALIGNANT FIBROUS HISTIOCYTOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MALIGNANT FIBROUS HISTIOCYTOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MALIGNANT FIBROUS HISTIOCYTOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MALIGNANT FIBROUS HISTIOCYTOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MALIGNANT FIBROUS HISTIOCYTOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MALIGNANT FIBROUS HISTIOCYTOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MALIGNANT FIBROUS HISTIOCYTOMA - UNMET NEEDS
10 MALIGNANT FIBROUS HISTIOCYTOMA - KEY ENDPOINTS OF TREATMENT
11 MALIGNANT FIBROUS HISTIOCYTOMA - MARKETED PRODUCTS
11.1 List of Malignant Fibrous Histiocytoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MALIGNANT FIBROUS HISTIOCYTOMA - PIPELINE DRUGS
12.1 List of Malignant Fibrous Histiocytoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Envafolimab - Alphamab Oncology/Ascletis/3D Medicine
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. MALIGNANT FIBROUS HISTIOCYTOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MALIGNANT FIBROUS HISTIOCYTOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MALIGNANT FIBROUS HISTIOCYTOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Malignant Fibrous Histiocytoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Malignant Fibrous Histiocytoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Malignant Fibrous Histiocytoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Malignant Fibrous Histiocytoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Malignant Fibrous Histiocytoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Malignant Fibrous Histiocytoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Malignant Fibrous Histiocytoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Malignant Fibrous Histiocytoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Malignant Fibrous Histiocytoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Malignant Fibrous Histiocytoma - Access and Reimbursement Overview
16 MALIGNANT FIBROUS HISTIOCYTOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MALIGNANT FIBROUS HISTIOCYTOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MALIGNANT FIBROUS HISTIOCYTOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
